Composition and Method for Curing Migraine Headaches

Abstract

The invention is directed to methods and compositions for curing migraine headaches. In particular, compositions are described involving the combination of dexamethasone, lidocaine, and thiamine. The methods of curing a patient of migraines having trigeminal or occipital neuralgia involves administering, by subcutaneous injection during a single treatment session, a combination of dexamethasone, lidocaine and thiamine to several craniofacial nerves.

I claim: 
     
         1 . A pharmaceutical composition for curing migraine headaches comprising:
 dexamethasone,   lidocaine, and   thiamine,   wherein the pharmaceutical composition is capable of eliminating the recurrence of migraines upon a single treatment session.   
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein dexamethasone is present in the range of about 12 mg to 16 mg per treatment session, lidocaine is present in the range of about at about 60 mg to 80 mg per treatment session, and thiamine is present in the range of about 100 mg to 200 mg per treatment session. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein dexamethasone is present at about 12 mg per treatment session, lidocaine is present at about 60 mg per treatment session, and thiamine is present at about 100 mg per treatment session. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition has a ratio of dexamethasone to lidocaine to thiamine present in the amount of about 1 mg to 5 mg to 8.3 mg, respectively. 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein dexamethasone is in the form of dexamethasone phosphate. 
     
     
         6 . The pharmaceutical composition of  claim 1 ,
 wherein dexamethasone is in the form of a pharmaceutical acceptable salt, solvate, metabolite or racemate;   wherein lidocaine is a pharmaceutically acceptable salt, solvate, metabolite or racemate thereof; and,   wherein thiamine is in the form of a pharmaceutically acceptable salt, solvate, metabolite or racemate thereof, such that the subject is treated.   
     
     
         7 . A method of curing migraine headaches in a patient having recurring migraine headaches comprising:
 administering a pharmaceutical composition having:
 dexamethasone, 
 lidocaine, and 
 thiamine, 
   wherein administering said composition is capable of eliminating the recurrence of migraines upon a single treatment session.   
     
     
         8 . The method of  claim 7 , wherein dexamethasone is administered in an amount of approximately between 12 mg to 16 mg per treatment session, thiamine is administered in an amount of approximately between 100 mg to 200 mg per treatment session, and lidocaine is administered in an amount of approximately between 60 mg to 80 mg per treatment session. 
     
     
         9 . The method of  claim 7 , wherein dexamethasone is administered in an amount of about 12 mg per treatment session, thiamine is administered in an amount of approximately 100 mg per treatment session, and lidocaine is administered in an amount of approximately 60 mg to per treatment session. 
     
     
         10 . The method of  claim 7 , wherein the pharmaceutical composition has a ratio of dexamethasone to lidocaine to thiamine in the amount of about 1 mg to 5 mg to 8.3 mg, respectively. 
     
     
         11 . The method of  claim 10 , wherein administering said pharmaceutical composition is characterized as administering dexamethasone, thiamine, and lidocaine to at least ten craniofacial regions. 
     
     
         12 . The method of  claim 7 , wherein said patient having recurring migraines has recurring migraine headaches caused by trigeminal or occipital neuralgia. 
     
     
         13 . The method of  claim 7 , further comprises administering said pharmaceutical composition to ganglia associated peripheral nerves. 
     
     
         14 . The method of  claim 7 , wherein administering said pharmaceutical composition is characterized as administering said composition in proximity to the retro-orbital nerve branch associated with a ciliary ganglion. 
     
     
         15 . The method of  claim 7 , wherein administering said pharmaceutical composition is characterized as administering said pharmaceutical composition to the second and third spinal nerve. 
     
     
         16 . The method of  claim 7 , wherein administering said pharmaceutical composition is characterized as administering said pharmaceutical composition in proximity to the frontal nerve. 
     
     
         17 . The method of  claim 7 , wherein administering said pharmaceutical composition is characterized as administering in a single treatment session, separate injections in proximity to at least one of the following: the frontal nerve, supratrochlear nerve, retro-orbital nerve, zygomatic nerve branches, nasal mucosa, infraalveolar branch of the mandibular nerve, first and second trigeminal nerve division, pterygopalatine ganglion, greater occipital nerve, lesser occipital nerve, second spinal nerve, and third spinal nerve. 
     
     
         18 . The method of  claim 7 , wherein administering said pharmaceutical composition is characterized as administering in a single treatment session, separate injections in proximity to at least three of the following: the frontal nerve, supratrochlear nerve, retro-orbital nerve, zygomatic nerve branches, nasal mucosa, infraalveolar branch of the mandibular nerve, first and second trigeminal nerve division, pterygopalatine ganglion, greater occipital nerve, lesser occipital nerve, second spinal nerve, and third spinal nerve. 
     
     
         19 . The method of  claim 7  wherein administering said composition is characterized as administering to the subject (1) an amount of dexamethasone, a pharmaceutical acceptable salt, solvate, metabolite or racemate thereof, (2) an amount of lidocaine, a pharmaceutically acceptable salt, solvate, metabolite or racemate thereof, and (3) an amount of thiamine, a pharmaceutically acceptable salt, solvate, metabolite or racemate thereof 
     
     
         20 . A pharmaceutical composition for curing migraine headaches consisting of the active pharmaceutical ingredients of:
 dexamethasone,   lidocaine, and   thiamine,   wherein the pharmaceutical composition is capable of eliminating the recurrence of migraines upon a single treatment session.